Pfizer, Incorporated (PFE)

SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Jeffrey B. Kindler , CEO/Chairman of the Board/Director
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Jeffrey B. Kindler, CEO/Chairman of the Board/Director

235 East 42nd Street

New York, NY 10017

US Map it

Phone: (212) 573-2323

Fax: (212) 573-7851

www.pfizer.com



Overview

A research-based, global pharmaceutical company which discovers, develops, manufactures and markets prescription medicines for humans and animals.

Portfolio Articles

See more news on this company

Portfolio Blogs
News From Around the Web
powered by  inform

Employees

Number of Employees: 86,600
Revenue per Employee: $496,051

Top Executives

Margaret M. Foran, Divisional Senior VP/Secretary/Other Corporate Officer
Martin Mackay, President, Divisional/Senior VP
Natale S. Ricciardi, Divisional President/Senior VP

William C. Steere, Jr., Director/Other Corporate Officer
Allen P. Waxman, General Counsel/Senior VP
Loretta V. Cangialosi, Vice President/Controller

Dr.Corey S. Goodman, Ph.D., President, Divisional/Senior VP
M. Anthony Burns, Director/Other Corporate Officer

Ian C. Read, President, Divisional/Senior VP
Dr. Joseph M. Feczko, Chief Medical Officer/Senior VP
Sally Susman, Senior VP/Other Executive Officer

Mary S. McLeod, Senior VP, Divisional
Richard H. Bagger, Senior VP, Divisional

Board of Directors

Margaret M. Foran, Divisional Senior VP/Secretary/Other Corporate Officer

William C. Steere, Jr., Director/Other Corporate Officer

Dr. Dana G. Mead, Director
M. Anthony Burns, Director/Other Corporate Officer
Robert N. Burt, Director

William R. Howell, Director
James M. Kilts, Director

Financials

Quarterly
Annual

Income Statement 07/2008 04/2008 01/2008 10/2007
Sales 2.95 Bil. 2.76 Bil. 3.38 Bil. 4.02 Bil.
Gross Operating Profit 9.18 Bil. 9.08 Bil. 9.68 Bil. 7.97 Bil.
Operating Income before D & A (EBITDA) 3.35 Bil. 3.8 Bil. 2.77 Bil. 2.2 Bil.
Total Income Before Interest Expenses (EBIT) 2.79 Bil. 3.56 Bil. 3.16 Bil. 636 Mil.
Total Net Income 2.78 Bil. 2.78 Bil. 2.88 Bil. 761 Mil.
Basic EPS, Total 0.41 0.41 0.42 0.11
Diluted EPS, Total 0.41 0.41 0.42 0.11

BALANCE STATEMENT 07/2008 04/2008 01/2008 10/2007
Cash and Equivalents NA NA NA 2.61 Bil.
Total Assets NA NA NA 41.84 Bil.
Total Liabilities NA NA NA 14.33 Bil.
Total Capitalization NA NA NA 72.65 Bil.

Cash Flow 07/2008 04/2008 01/2008 10/2007
Net Cash From Continuing Operations NA NA NA 9.45 Bil.
Net Cash From Investing Activities NA NA NA 3.59 Bil.
Net Cash From Financing Activities NA NA NA -12.41 Bil.
Net Change in Cash & Cash Equivalents NA NA NA 784 Mil.

powered by Interactive Data

Income Statement 2008 2007 2006 2005
Sales 14.37 Bil. 5.61 Bil. 6.36 Bil. 5.81 Bil.
Gross Operating Profit 34.25 Bil. 42.76 Bil. 44.94 Bil. 46.7 Bil.
Operating Income before D & A (EBITDA) 10.53 Bil. 19.58 Bil. 20.5 Bil. 22.12 Bil.
Total Income Before Interest Expenses (EBIT) 9.47 Bil. 13.52 Bil. 12 Bil. 14.35 Bil.
Total Net Income 7.68 Bil. 19.34 Bil. 8.08 Bil. 11.36 Bil.
Basic EPS, Total 1.2 2.67 1.1 1.51
Diluted EPS, Total 1.2 2.66 1.09 1.49

BALANCE STATEMENT 2008 2007 2006 2005
Cash and Equivalents NA 1.83 Bil. 2.25 Bil. 1.81 Bil.
Total Assets NA 46.95 Bil. 41.9 Bil. 39.69 Bil.
Total Liabilities NA 21.39 Bil. 28.45 Bil. 26.46 Bil.
Total Capitalization NA 76.9 Bil. 71.97 Bil. 75.56 Bil.

Cash Flow 2008 2007 2006 2005
Net Cash From Continuing Operations NA 27.84 Bil. 14.73 Bil. 16.34 Bil.
Net Cash From Investing Activities NA 5.1 Bil. -5.07 Bil. -9.42 Bil.
Net Cash From Financing Activities NA -23.1 Bil. -9.22 Bil. -6.63 Bil.
Net Change in Cash & Cash Equivalents NA -420 Mil. 439 Mil. 288 Mil.

powered by Interactive Data







News Volume

31 days volume

100%
80%
60%
40%
20%
0
September
October

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented